Molecular Templates
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 62
- Market Cap
- -
- Website
- http://www.mtem.com
- Introduction
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
- Conditions
- Renal Cell CarcinomaMesotheliomaCervical CancerMelanomaMismatch Repair DeficiencyUrothelial CarcinomaMicrosatellite Instability HighNon Small Cell Lung CancerEsophageal Squamous Cell CarcinomaHepatocellular Carcinoma
- Interventions
- Drug: MT-8421Drug: Nivolumab
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06034860
- Locations
- 🇺🇸
The Angeles Clinic, Los Angeles, California, United States
🇺🇸Horizon Oncology Research, LLC, Lafayette, Indiana, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
- Conditions
- Advanced Solid TumorSquamous Cell Carcinoma of Head and NeckNon-small Cell Lung Cancer
- Interventions
- Drug: MT-6402
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04795713
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Study of MT-5111 in HER2-positive Solid Tumors
- Conditions
- HER2-positive Solid Cancers
- Interventions
- Drug: MT-5111 (experimental study drug)
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04029922
- Locations
- 🇺🇸
UCLA Hematology & Oncology, Santa Monica, California, United States
🇺🇸BRCR Medical Center, Plantation, Florida, United States
🇦🇺Cancer Research South Australia, Adelaide, South Australia, Australia
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT04017130
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Vanderbilt University Medical Center- Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Miami University, Miami, Florida, United States
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
- Conditions
- Non-hodgkin Lymphoma
- Interventions
- Drug: MT-3724
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03645395
- Locations
- 🇺🇸
University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Boca Raton Clinical Research, Plantation, Florida, United States
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
- Conditions
- Non-hodgkin Lymphoma,B CellRefractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03488251
- Locations
- 🇺🇸
UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Good Samaritan Hospital, Cincinnati, Ohio, United States
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
- Conditions
- Non-Hodgkin's B-cell Lymphoma
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2019-10-11
- Lead Sponsor
- Molecular Templates, Inc.
- Registration Number
- NCT02715843
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic B-cell Lymphocytic LeukemiaSmall Lymphocytic Leukemia
- Interventions
- Drug: MT-3724
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Molecular Templates, Inc.
- Registration Number
- NCT02556346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL
- Conditions
- Hematological MalignancyLeukemia, Lymphocytic, Chronic, B-CellSmall Lymphocytic LeukemiaNon-Hodgkin's B-cell LymphomaDiffuse Large B Cell LymphomaBlood Cancer
- Interventions
- Drug: MT-3724 Phase 1Drug: MT-3724 Phase 2
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Molecular Templates, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT02361346
- Locations
- 🇺🇸
BRCR Medical Center, Plantation, Florida, United States
🇨🇦Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States